EUROFINS
23.6.2022 09:03:12 CEST | Business Wire | Press release
Gold Standard Diagnostics Europe continues its response to the threat of emerging infectious diseases by developing a new multiplex Real-time PCR assay for the detection of the monkeypox virus and its differentiation from other orthopox viruses.
The monkeypox virus has raised significant concerns given its recent spread, with more than 2500 confirmed cases in 37 countries [1]. These cases are especially unusual as they have not occurred among travelers returning from the tropical rainforest regions of Central and West Africa, the common circulation area for the virus. The Centers for Disease Control and Prevention (CDC) has issued an alert level 2 for the monkeypox virus.
With the current uncertainty surrounding the clinical implications of the monkeypox virus, it is crucial to closely monitor its spread and provide reliable diagnostic solutions for its identification. This virus belongs to the Orthopoxvirus genus, which encompasses pathogenic viruses like smallpox (Variola virus; eradicated), cowpox or buffalopox, which exhibit similar symptoms in infected patients.
The Mplex Monkeypox, Orthopox Real-time PCR assay uses a generic target for orthopox viruses and a specific target for monkeypox and will be available for research use only from the beginning of July. This product complements Gold Standard Diagnostics Europe’s suite of assays developed in response to infectious diseases, such as the GSD NovaPrime and NovaType assay families, developed for SARS-CoV-2 detection and variant identification.
Reference
[1] https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html
For more information, please visit Eurofins Technologies website.
About Eurofins Technologies – a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection methods
Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast-growing global provider of diagnostic technologies and industry-leading ELISA-based instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 58,000 staff across a network of 900 laboratories in 54 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005096/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coulson Aviation Defines the Next Chapter of Innovation With EmberWorks10.9.2026 14:03:00 CEST | Press release
Dedicated division connects operational experience with the development and testing of new wildfire and emergency-response technologies. Coulson Aviation is moving forward with EmberWorks, its dedicated innovation division created to turn real-world operational challenges into new capabilities for aerial firefighting, aviation, and emergency response. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910644135/en/ Comparison imagery demonstrates how ORBIT uses airborne thermal sensing and automated processing to identify wildfire activity and generate geolocated fire intelligence. First introduced at the Aerial Fire Fighting Global Conference in Rome earlier this year, EmberWorks formalizes an approach to innovation that has existed throughout Coulson’s history. From aircraft modification and mission-system development to programs such as C-130 airtanker, Boeing 737 Fireliner, and CH-47 Chinook helicopter, Coulson has long d
Radisys Launches V.AI Ecosystem to Accelerate Telecom AI Service Innovation10.9.2026 14:00:00 CEST | Press release
Combines turnkey applications, developer tools and leading voice and speech AI technologies from industry-leading partners, helping operators launch and monetize intelligent communications services faster Radisys® Corporation, a global leader in open telecom solutions, today announced the launch of its V.AI ecosystem, bringing together applications, development tools and leading voice and speech AI technologies to help telecom operators create, deploy and monetize AI-powered communication services for consumers and business subscribers. The V.AI ecosystem, which has evolved since the launch of the Radisys Engage Digital Platform (EDP) at MWC Barcelona in 2022, draws on two decades of Radisys leadership in real-time media processing and a global footprint across live operator networks. Seamlessly integrated with EDP, the ecosystem gives operators multiple paths to market. Operators can deploy turnkey applications, customize services for specific markets and customer segments, or create
Bending Spoons enters into a definitive agreement to acquire Miro for $1.355 billion10.9.2026 14:00:00 CEST | Press release
Bending Spoons S.p.A. (NASDAQ: BSP) has entered into a definitive agreement to acquire Miro at an enterprise value of $1.355 billion. Together with Miro’s net cash, this implies an equity value of approximately $1.79 billion. In connection with the all-cash transaction, certain Miro shareholders have agreed to invest $295 million of their proceeds into newly issued Bending Spoons equity. The acquisition, including the investment, is subject to customary closing conditions and approvals, including regulatory approvals. “It's a privilege, and no small responsibility, to welcome a product that over 250,000 organizations have integrated into their workflows,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Miro has grown to around $600 million in annual recurring revenue, nearly 90% from business and enterprise customers. After closing, we plan to invest substantially in the fundamentals that its customers value: performance, reliability, and functionality that supports critical col
Netskrt to Showcase Media Over QUIC Work with Oracle at IBC 202610.9.2026 14:00:00 CEST | Press release
Netskrt and Oracle to demonstrate end-to-end MOQ delivery and discuss the future of low-latency live streaming Netskrt, an independent content delivery network built for high-concurrency streaming events, today announced that it will showcase its work to advance Media Over QUIC (MOQ) at IBC 2026, taking place Sept. 11-14 at RAI Amsterdam. As part of the event, Netskrt will demonstrate with Oracle how independently operated CDN infrastructure can participate in a coordinated MOQ delivery path designed to bring live media closer to viewers. MOQ is an emerging IETF effort designed to support low-latency media delivery at scale, with live streaming among its primary use cases. Its relay-based architecture enables media to move through distributed infrastructure closer to audiences, creating new possibilities for reducing latency while efficiently serving highly concurrent live events. At IBC, Netskrt and Oracle will put that model into practice. An Oracle Video Edge (OVE) containerized rel
BioLife Secures U.S. Patent for First-of-its-kind Effervescent Oral Peptide Delivery Technology10.9.2026 14:00:00 CEST | Press release
Preclinical studies demonstrate measurable systemic semaglutide exposure following oral administration; granted claims cover semaglutide and multiple GLP-1 receptor agonists. BioLife today announced that the United States Patent and Trademark Office has granted U.S. Patent 12,667,605 B2 for its novel effervescent oral peptide delivery technology, designed to support current and future peptide therapeutics for obesity, diabetes and metabolic disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910717829/en/ BioLife offers a new solution for oral GLP-1 delivery The announcement comes as demand for GLP-1 medicines continues to accelerate. GLP-1 therapies generated approximately $132 billion in global sales in 2025, while obesity medicines now represent an estimated $42 billion market.1 As more patients seek alternatives to injections, demand for alternative oral treatments continues to grow. First generation oral GLP-1 me
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom